Advancements in Neuroendocrine Tumor Treatment by ITM
ITM Isotope Technologies Munich SE (ITM), a frontrunner in the radiopharmaceutical industry, is set to unveil significant insights from the post hoc subgroup analyses of its recent Phase 3 COMPETE trial. This event will take place during the prestigious North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium scheduled from October 22 to October 25. The symposium will convene in Austin to unite experts in the field of neuroendocrine tumors, focusing on innovative treatment approaches.
Details of the Oral Presentation
During the symposium, a pivotal oral presentation will be delivered, showcasing the efficacy of 177Lu-edotreotide compared to everolimus in patients diagnosed with Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This presentation, titled Efficacy of 177Lu-edotreotide vs Everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses), is scheduled for Friday, October 24, from 3:35 pm to 4:50 pm CDT. The session will be featured among noted abstracts addressing advancements in targeted therapies and molecular imaging.
Information About the Presenter
The presentation will be conducted by Dr. Jaume Capdevila, a distinguished investigator and senior medical oncologist at Vall d'Hebron University Hospital in Barcelona. His presentation will convey crucial findings that emphasize the effectiveness of targeted therapies in managing neuroendocrine tumors.
Satellite Symposium on Novel Therapeutic Strategies
In addition to the oral presentation, ITM will also facilitate a satellite symposium titled What’s Your Next Move? Sequencing Therapies in GEP-NETs. Scheduled for the same day, from 7:00 am to 8:00 am CDT, this symposium will be moderated by Dr. Namrata Vijayvergia, a respected figure in gastrointestinal medical oncology. She will be joined by a panel of experts, including Dr. Jessica Maxwell, Dr. Jonathan Strosberg, and Dr. Harshad Kulkarni, who will discuss innovative strategies for sequencing therapies in neuroendocrine cancer care.
Insights from the COMPETE Trial
The COMPETE trial (NCT03049189) has made significant strides in the evaluation of 177Lu-edotreotide (ITM-11) as a proprietary, synthetic targeted radiotherapeutic agent. This investigational treatment demonstrated a remarkable improvement in progression-free survival when compared with everolimus among patients with inoperable and progressive GEP-NETs. Such findings are instrumental in establishing more effective treatment protocols for this challenging subset of patients.
About ITM Isotope Technologies Munich SE
As a leader in the radiopharmaceutical sector, ITM is committed to pioneering new generations of therapeutics and diagnostics targeted at complex tumors. Their mission includes fulfilling the expectations of patients and medical professionals by excelling in the development, production, and global supply of medical isotopes. ITM aims to enhance patient outcomes through their advanced precision oncology pipeline, which includes numerous ongoing Phase 3 studies that combine high-quality radioisotopes with various targeting molecules.
With over two decades of experience in radiopharmaceutical research and development, ITM is strategically positioned to make significant contributions to cancer treatment. Their continuous efforts focus on delivering targeted therapies that aim to maximize clinical benefits and improve the patients' quality of life.
Contact Information for ITM
For further inquiries, ITM encourages interested parties to reach out through their corporate communications team or investor relations:
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
Frequently Asked Questions
What will ITM present at the NANETS symposium?
ITM will present data from the post hoc analyses of its Phase 3 COMPETE trial, highlighting the effectiveness of 177Lu-edotreotide in treating GEP-NETs.
Who is the presenter of the Phase 3 COMPETE trial findings?
Dr. Jaume Capdevila, a senior medical oncologist, will present the findings at the symposium.
When and where will the satellite symposium occur?
The satellite symposium titled What’s Your Next Move? will occur on October 24, from 7:00 am - 8:00 am CDT at the JW Marriott Austin.
What are GEP-NETs?
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that can develop in the gastrointestinal tract and pancreas, and treatment options are limited.
How can I contact ITM for more information?
You can contact ITM's corporate communications team or investor relations through the provided email addresses or phone numbers.
